The number of employees laid off and companies letting people go increased year over year during the first half of 2025. BioSpace recaps the five largest layoff rounds, including cuts at Bayer, BMS ...

Biogen expects to record a $46 million expense as part of its second quarter earnings. The Cambridge, Mass., biotechnology company said Monday the expense is an in-process research and development, ...

On the morning of February 18, 2005, Biogen Idec of Cambridge, Massachusetts, learned that two patients in a clinical trial of its recently approved MS drug Tysabri (natalizumab) were suspected of ...

Assessing the distribution of a medication in the brain is critical for the treatment of a vast range of neurological ...

CAMBRIDGE, MA, USA I June 30, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 ...

A new building of condominiums — including three affordable units — has been proposed for Brighton Center. Biotech's Future - ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SP ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who ...

The problems cut across the industry as a whole. Many publicly traded biotech companies are now valued at less than the cash ...

The Cambridge, Mass., biotechnology company said that based on the encouraging data, it is engaging with regulators to advance salanersen to registrational-stage studies.

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

Biogen Launches Phase 3 Pediatric Trial Of Omaveloxolone For Friedreich Ataxia. Published on June 23, 2025 at 1:36 am by Fatima Gulzar in News ...